[go: up one dir, main page]

WO2004056386A3 - Nucleic acids involved in blood-brain barrier control - Google Patents

Nucleic acids involved in blood-brain barrier control Download PDF

Info

Publication number
WO2004056386A3
WO2004056386A3 PCT/NL2003/000915 NL0300915W WO2004056386A3 WO 2004056386 A3 WO2004056386 A3 WO 2004056386A3 NL 0300915 W NL0300915 W NL 0300915W WO 2004056386 A3 WO2004056386 A3 WO 2004056386A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood
polypeptides
brain
nucleic acids
brain barrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2003/000915
Other languages
French (fr)
Other versions
WO2004056386A2 (en
Inventor
Pieter Jaap Gaillard
Boer Albertus Gerrit De
Arjen Brink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TO BBB Holding BV
Original Assignee
TO BBB Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TO BBB Holding BV filed Critical TO BBB Holding BV
Priority to AU2003295268A priority Critical patent/AU2003295268A1/en
Publication of WO2004056386A2 publication Critical patent/WO2004056386A2/en
Publication of WO2004056386A3 publication Critical patent/WO2004056386A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing dynamic changes in blood-brain barrier formation. Such polypeptides are referred to as Pro-Barrier (PB) polypeptides herein. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain barrier properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-PB polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of PB polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.
PCT/NL2003/000915 2002-12-19 2003-12-19 Nucleic acids involved in blood-brain barrier control Ceased WO2004056386A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003295268A AU2003295268A1 (en) 2002-12-19 2003-12-19 Nucleic acids involved in blood-brain barrier control

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02080503.2 2002-12-19
EP02080503 2002-12-19
US46523403P 2003-04-25 2003-04-25
US60/465,234 2003-04-25

Publications (2)

Publication Number Publication Date
WO2004056386A2 WO2004056386A2 (en) 2004-07-08
WO2004056386A3 true WO2004056386A3 (en) 2005-02-24

Family

ID=32683815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2003/000915 Ceased WO2004056386A2 (en) 2002-12-19 2003-12-19 Nucleic acids involved in blood-brain barrier control

Country Status (2)

Country Link
AU (1) AU2003295268A1 (en)
WO (1) WO2004056386A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
CA2683127A1 (en) * 2006-10-09 2008-04-17 Government Of The United States Of America As Represented By The Secreta Ry Of The Department Of Health And Human Services National Institutes Of Treatment of inflammation, demyelination and neuronal/axonal loss
US20100168382A1 (en) * 2007-06-12 2010-07-01 Vladimir Berezin Neuroplastin derived peptides
WO2014004424A1 (en) 2012-06-26 2014-01-03 Temple University - Of The Commonwealth System Of Higher Education Method for detecting injury to the brian
JPWO2014097875A1 (en) * 2012-12-20 2017-01-12 国立大学法人鳥取大学 Pluripotent stem cells using a novel dedifferentiation induction method
WO2021113512A1 (en) * 2019-12-04 2021-06-10 The Board Of Trustees Of The Leland Stanford Junior University Enhancing blood-brain barrier drug transport by targeting endogenous regulators
CN115925800A (en) * 2023-01-18 2023-04-07 福州海洋研究院 Fish soluble calcium chelate protein peptide and preparation method thereof
CN119219739B (en) * 2024-11-29 2025-03-28 浙江农林大学 Walnut derived peptide with function of clearing Abeta and high antioxidation and improving learning and memory and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016662A1 (en) * 1994-11-30 1996-06-06 The University Of Birmingham Growth factor expression in human pregnant cervix
WO1999035290A1 (en) * 1998-01-08 1999-07-15 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
EP1103607A1 (en) * 1999-11-23 2001-05-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Enhancement of tmTNF levels for the sensitisation of tumours to sTNF and/or cytostatic drugs
WO2001045751A1 (en) * 1999-12-22 2001-06-28 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016662A1 (en) * 1994-11-30 1996-06-06 The University Of Birmingham Growth factor expression in human pregnant cervix
WO1999035290A1 (en) * 1998-01-08 1999-07-15 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
EP1103607A1 (en) * 1999-11-23 2001-05-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Enhancement of tmTNF levels for the sensitisation of tumours to sTNF and/or cytostatic drugs
WO2001045751A1 (en) * 1999-12-22 2001-06-28 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAILLARD PIETER JAAP ET AL: "Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes.", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 12, no. 3, January 2001 (2001-01-01), pages 215 - 222, XP002235519, ISSN: 0928-0987 *
GAILLARD PIETER JAAP ET AL: "Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug.", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 12, no. 2, December 2000 (2000-12-01), pages 95 - 102, XP002235518, ISSN: 0928-0987 *
KEVIL C G ET AL: "Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junction proteins", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 24, 12 June 1998 (1998-06-12), pages 15099 - 15103, XP002940074, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2003295268A1 (en) 2004-07-14
WO2004056386A2 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
WO2004069870A3 (en) Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
Su et al. Transcranial ultrasound stimulation promotes brain-derived neurotrophic factor and reduces apoptosis in a mouse model of traumatic brain injury
US8318136B2 (en) Methods and systems for neural maintenance and regeneration
KR20200143407A (en) Neurotoxin for use in inhibiting CGRP
ATE426408T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM TOXIN AND HUMAN SERUM ALBUMINE
DE69836131D1 (en) NEW HUMAN DELTA3 COMPOSITION AND ITS THERAPEUTIC AND DIAGNOSTIC USES
Waggoner et al. Porous silicon nanoparticles targeted to the extracellular matrix for therapeutic protein delivery in traumatic brain injury
EP3958889B1 (en) Collagen mimetic peptide compositions for treating a posterior segment ocular disease or disorder involving the retina, retinal blood vessels, retinal nerves or optic nerve
KR20190067219A (en) Use of neurotoxic injury-related polypeptides in pain prevention, relief or treatment
WO2004056386A3 (en) Nucleic acids involved in blood-brain barrier control
KR102405411B1 (en) Treatment of damaged nerve with pten inhibitor
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
CN104105501B (en) Treatment of allodynia, hyperalgesia, spontaneous pain, and phantom pain
KR20040008177A (en) Method of Preventing Cell Death Using Segments of Neural Thread Proteins
EP1947116A3 (en) Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
KR20210054542A (en) Methods and compositions for inducing neuroplasticity
JP2005508875A5 (en)
Toledano et al. A SEMA3E mutant resistant to cleavage by furins (UNCL-SEMA3E) inhibits choroidal neovascularization
Gao et al. The therapeutic potentials of neurotrophic factors for diseases of the nervous system
Jang et al. Blood vessel maturation by disintegrin in oxygen-induced retinopathy
KR20220007122A (en) Methods and drugs for the treatment of amyotrophic lateral sclerosis
HUP0003831A2 (en) Tissue factor for influencing blood vessel formation
WO2001034183A3 (en) Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
WO2007043629A1 (en) Method of inhibiting angiogenesis by using ephrin b2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP